Estimated Control Closed Transaction verified CPGpersonalized supplementsSupplementsVitamins & Supplements

Thorne HealthTech acquired by L Catterton

L Catterton acquired Thorne HealthTech, a vitamins & supplements brand, on Oct 16, 2023.

Transaction summary

Target
Thorne HealthTech
Seller
-
Announced
2023-08-28
Geography
-
Type
Acquisition
Deal type
Control
Stake acquired
-
First added
2026-06-19
Latest update
2026-07-13

Parties at the deal date

Acquirer

L Catterton

Current investor profile →

L Catterton is one of the world's leading consumer products focused private equity firms. L Catterton has deep expertise in consumer products, having made more than 200 investments since 1989, and being co-owned by LVMH (which owns brands including Louis Vuitton). We are able to provide our portfolio companies with access to substantial in-house and external resources to drive operational improvements and further growth. L Catterton has five current consumer brand investing platforms: a Flagship Buyout fund focused on $50-400m investments in North American and European companies, a North American Growth fund focused on $10-50m investments, a Latin American Fund focused on $40-75m investments, a Western Europe fund focused on EUR 25-75m investments, and an Asia fund focused on $50-150m investments. L Catterton also has a real estate fund that invests as a co-developer in large scale, mixed-use projects anchored by luxury retail. L Catterton was formed in 2016 through the merger of L Capital (the PE arm of LVMH) and Catterton, a US Private Equity firm.

Snapshot preserved for this transaction; current company profiles may differ.

Value and multiples

100% enterprise value

USD 681M

100% enterprise value | USD

Basis: Public source

Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.

EV / revenue

3.7x

Period not stated

Basis: FundComb estimate

EV / EBITDA

21.2x

EBITDA: normalised / adjusted

Basis: Derived from source data

Basis

  • EBITDA = $681,000,000 implied TEV / 21.2x = $32,122,642. Source: https://www.sec.gov/Archives/edgar/data/1844280/000119312523251140/d472624dsc14d9a.htm

Other reviewed estimates

Earlier estimates and their sources.

Thorne HealthTech Schedule 14D-9/A
EBITDA USD 32.1m | EV / revenue 3.7x | EV / EBITDA 21.2x
Open evidence
Thorne HealthTech Schedule 14D-9/A
EBITDA USD 32.1m | EV / revenue 3.7x | EV / EBITDA 21.2x
Open evidence
Thorne HealthTech Schedule 14D-9/A
EBITDA USD 32.1m | EV / revenue 3.7x | EV / EBITDA 21.2x
Open evidence
Thorne HealthTech Schedule 14D-9/A
EBITDA USD 32.1m | EV / revenue 3.7x | EV / EBITDA 21.2x
Open evidence

Source summary

Thorne HealthTech, Inc. Enters into Definitive Agreement to be Acquired by L Catterton for $10.20 Per Share in Cash - PR Newswire

Confirmed
Open via Google News

Thorne HealthTech Schedule 14D-9/A

Estimated

Amended solicitation/recommendation statement discloses Canaccord precedent transaction analysis and proposed Thorne transaction implied TEV and LTM Adjusted EBITDA multiple.

Open source

Continue your research

Explore more comps →